Keywords: Baxter Int, Momenta, Biosimilars, Follow-on biologics

Baxter taps Momenta expertise on biosimilars

Article | 28 December 2011

Print This

In another move to capitalize on the anticipated flood of biosimilars coming to the market, as blockbuster biological drugs come ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in